Ken Griffin Plus Therapeutics, Inc. Transaction History

Citadel Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.48 - $7.5 $8,050 - $125,790	16,772 New	16,772 $7,000
Q1 2022 May 16, 2022	SELL	$0.87 - $1.32 $72,339 - $109,756	-83,149 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$1.03 - $1.94 $85,643 - $161,309	83,149 New	83,149 $87,000
Q3 2021 Nov 15, 2021	SELL	$1.83 - $2.46 $79,658 - $107,081	-43,529 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$2.0 - $2.89 $87,058 - $125,798	43,529 New	43,529 $111,000
Q1 2021 May 17, 2021	SELL	$2.1 - $3.75 $26,138 - $46,676	-12,447 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$2.0 - $2.76 $20,424 - $28,185	-10,212 Reduced 45.07%	12,447 $25,000
Q3 2020 Nov 16, 2020	BUY	$2.11 - $3.17 $47,810 - $71,829	22,659 New	22,659 $58,000
Q1 2020 May 15, 2020	SELL	$1.05 - $2.85 $16,343 - $44,360	-15,565 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$1.99 - $3.23 $30,974 - $50,274	15,565 New	15,565 $37,000

Ticker PSTV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,601,400
Market Cap $43M
Description
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, lep...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.